Orap (Pimozide)

Pimozide, the active ingredient in Orap, is a typical antipsychotic presented as a tablet for oral use. It is used to manage symptoms of Tourette syndrome and certain forms of schizophrenia in adults and adolescents. GNH USA supplies Orap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pimozide is indicated for disorders that involve dopaminergic dysregulation, primarily within the central nervous system. - Tourette syndrome: reduces the frequency and severity of motor and vocal tics. - Chronic schizophrenia: alleviates psychotic symptoms such as delusions and hallucinations. - Persistent behavioral disorders: helps control severe repetitive behaviors when other therapies are insufficient.

Pimozide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation: feeling unusually drowsy or sleepy. - Extrapyramidal symptoms: muscle stiffness, tremor, or restlessness. - Dry mouth: reduced salivation leading to discomfort. - Constipation: slowed gastrointestinal motility. - Blurred vision: temporary visual disturbances. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Tardive dyskinesia: involuntary, repetitive movements that may be irreversible. - Neuroleptic malignant syndrome: life‑threatening reaction with fever, muscle rigidity, and autonomic instability. - QT interval prolongation: risk of serious cardiac arrhythmias. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Agranulocytosis: dangerously low white‑blood‑cell count increasing infection risk.

Before initiating pimozide therapy, several safety considerations should be reviewed. - Cardiac monitoring: obtain baseline ECG and monitor QT interval during treatment. - QT prolongation risk: avoid in patients with known prolonged QT or electrolyte disturbances. - Hepatic impairment: adjust dose or monitor liver function tests closely. - Elderly patients: increased susceptibility to falls and orthostatic hypotension. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pimozide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise pimozide plasma levels and increase toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower pimozide concentrations, reducing efficacy. - Other QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antihypertensives: pimozide may enhance blood‑pressure‑lowering effects. - Concurrent antipsychotics: increased likelihood of extrapyramidal symptoms. - Alcohol: potentiates central nervous system depression and sedation.